"Clearview Cancer Institute is north Alabamas leading cancer treatment center. For over 30 years we've provided leading-edge treatment & compassion."

During the past decade, Oncology Specialties, PC; Clearview Cancer Institute conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 4 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oncology Specialties, PC; Clearview Cancer Institute" #1 sponsor was "Celgene" with 5 trials, followed by "BeiGene" with 1 trials sponsored, "Biodesix, Inc." with 1 trials sponsored, "EGEN, Inc." with 1 trials sponsored and "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oncology Specialties, PC; Clearview Cancer Institute" #1 collaborator was "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "The Leukemia and Lymphoma Society" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Oncology Specialties, PC; Clearview Cancer Institute" are "Waldenstrom Macroglobulinemia" (2 trials), "B Cell Non-Hodgkin's Lymphoma" (1 trials), "Basal Cell Carcinoma" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials) and "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma" (1 trials). Many other conditions were trialed in "Oncology Specialties, PC; Clearview Cancer Institute" in a lesser frequency.

Most popular intervention types in "Oncology Specialties, PC; Clearview Cancer Institute" are "Drug" (10 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "AVL-292" (1 trials), "Abraxane (Induction)" (1 trials), "Abraxane (Maintenance)" (1 trials) and "Albumin-bound paclitaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oncology Specialties, PC; Clearview Cancer Institute" are 11 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Oncology Specialties, PC; Clearview Cancer Institute". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Oncology Specialties, PC; Clearview Cancer Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Oncology Specialties, PC; Clearview Cancer Institute, 3 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Oncology Specialties, PC; Clearview Cancer Institute has several departments that took part in Clinical trials: "Clearview Cancer Institute" - 103 trials